Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1991:41 Suppl 1:25-30.
doi: 10.2165/00003495-199100411-00006.

Effects of ACE inhibition on renal haemodynamics in essential hypertension and hypertension associated with chronic renal failure

Affiliations
Clinical Trial

Effects of ACE inhibition on renal haemodynamics in essential hypertension and hypertension associated with chronic renal failure

R A Sánchez et al. Drugs. 1991.

Abstract

Angiotensin II has many actions in the kidney, including regulation and distribution of renal circulation and glomerular filtration, as well as effects on mesangial contraction and on the filtration coefficient. The reduction in circulating and intrarenal angiotensin II by angiotensin converting enzyme (ACE) inhibitors in essential hypertension is associated with a significant increase in renal blood flow and a decrease in filtration fraction, without changes in glomerular filtration rate. In addition, administration of ACE inhibitors can reduce proximal sodium reabsorption via changes in peritubular hydrostatic and oncotic forces resulting from the fall in postglomerular capillary resistance. In severe hypertension the state of the renal vasculature does not allow ACE inhibition to induce similar haemodynamic changes and, therefore, it cannot contribute to renal sodium handling that requires the recruitment of alternate mechanisms. In spite of this, ACE inhibitors may exert a protective effect on the renal function of patients with severe hypertension as well as in those with renal impairment, by lowering systemic and, probably, intraglomerular pressure, reducing proteinuria and slowing the progression of renal failure.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Hypertens Suppl. 1989 Sep;7(5):S3-9 - PubMed
    1. Am J Hypertens. 1989 Apr;2(4):244-52 - PubMed
    1. Medicine (Baltimore). 1978 Mar;57(2):167-78 - PubMed
    1. J Hypertens Suppl. 1983 Oct;1(1):87-91 - PubMed
    1. J Clin Invest. 1986 Jun;77(6):1993-2000 - PubMed

Publication types

MeSH terms

LinkOut - more resources